Strong Revenue Growth:
Recent results show year-over-year increases in revenue and test volumes through 2025 and early 2026. Expanding U.S. adoption and rising Galleri volumes are cited as key contributors.
Strategic Partnerships:
Announcements include Epic EHR integration to streamline ordering and results across many health systems, supporting broader access. International and channel collaborations, including Samsung-linked expansion plans, are positioned to extend reach.
Investor Backing & Capital Strength:
Post–Illumina spin‑off funding and subsequent equity raises point to a multiyear cash runway. Additional financing provides flexibility to pursue regulatory, reimbursement, and commercialization goals.
